Lampalizumab fails to prevent geographic atrophy growth

• Posted on: Jul 11 2018
• By: Saratoga Opthalmology
• Leave a response

Investigators report data from 2 randomized phase 3 trials assessing the safety and efficacy of lampalizumab, a complement factor D inhibitor, for the treatment of geographic atrophy.
Source: AAO

Posted in: Uncategorized